Video
Dr. Cookson on darolutamide data: “An exciting move forward”
Author(s):
“This concept of adding additional therapy early on is ready for primetime,” says Michael S. Cookson, MD, MMHC.
Video Player is loading.
In this video, Michael S. Cookson, MD, MMHC, shares insights from the study, “Darolutamide in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer: overall survival and other outcomes of the phase 3 ARASENS trial,” which will be presented at the 2022 South Central Section of the AUA Annual Meeting in Coronado, California. professor and chair of urology at the University of Oklahoma Health Sciences Center in Oklahoma City, is co-editor in chief of Urology Times.®
Related Videos
Gopa Iyer, MD, highlights findings from FORAGER-1 in metastatic urothelial carcinoma
Michael Schweizer, MD, shares data on mevrometostat plus enzalutamide in mCRPC
Laura Bukavina, MD, highlights study of urinary microbiome profiling
Kate Gessner, MD, on the mechanisms of immunotherapy failure in RCC
Darren Feldman, MD, on clinical outcomes in R/R testicular germ cell tumors
ASCO GU recap: Insights on 5 key trials
Laurence Albiges, MD, on COSMIC-313 trial of triplet vs doublet combination in aRCC
Francesca Jackson-Spence, MRCP, on efficacy of savolitinib/durvalumab in papillary renal cancer
Gopa Iyer, MD, on durable efficacy of EV/pembrolizumab in urothelial carcinoma
David Braun, MD, on phase 2 trial of an individualized neoantigen therapy for RCC
Related Content
